Dainippon Sumitomo Pharma Receives Approval for Orally Disintegrating Formulation of Amlodin, Hypertension/Angina Pectoris Treatment.Tokyo, Japan, Mar 20, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Dainippon Sumitomo Pharma announced on March 17 that it has received approval for its proprietary ethical drugs, Amlodin OD Tablet 2.5mg/ 5mg, from the Ministry of Health, Labor and Welfare as of March 15. Produced using the company's proprietary formulation technology SUITAB, the orally disintegrating tablets The Food and Drug Administration's (FDA) definition of an orally disintegrating tablet (ODT) is: "A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue. are a calcium antagonist antagonist /an·tag·o·nist/ (an-tag´o-nist) 1. a substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response, blocking binding of substances that could indicated for the treatment of hypertension and angina pectoris angina pectoris (ănjī`nə pĕk`tərĭs), condition characterized by chest pain that occurs when the muscles of the heart receive an insufficient supply of oxygen. . The company will put on sale the product after the National Health Insurance listing. Amlodin has been widely prescribed in Japan since its release in 1993. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion